Researchers from Genethon, the AFM-Téléthon laboratory, Inserm (UMR 1089, Nantes) and the University of London (Royal Holloway) demonstrated the efficacy of an innovative gene therapy in the treatment of Duchenne muscular dystrophy. Indeed, after injecting microdystrophin (a “shortened” version of the dystrophin gene) via a drug vector, the researchers managed to restore muscle strength and stabilise the clinical symptoms in dogs naturally affected by Duchenne muscular dystrophy.
Teams at Genethon developed, in collaboration with a team at Royal Holloway University of London led by Pr. Dickson, and produced, a gene therapy drug combining an AAV-type viral vector with a shortened version of the dystrophin gene (approximately 4,000 base pairs), allowing the production of a functional protein. Dr Le Guiner’s team tested this innovative treatment in 12 dogs naturally affected by Duchenne muscular dystrophy. By injecting this microdystrophin intravenously, and hence into the whole body of the dogs, the researchers observed that dystrophin expression returned to a high level, and muscle function was significantly restored, with stabilisation of the clinical symptoms observed for over 2 years following injection of the drug. No immunosuppressive treatment was administered beforehand, and no sideeffects were observed.
Some Golden Retrievers develop Duchenne muscular dystrophy naturally. The successful treatment of these dogs, which show the same clinical symptoms as children with this disease, and are of a similar weight, is a decisive step toward developing the same treatment in children. “This preclinical study demonstrates the safety and efficacy of microdystrophin, and makes it possible to consider developing a clinical trial in patients. Indeed, this is the first time that it has been possible to treat the whole body of a large sized animal with this protein. Moreover, this innovative approach allows treatment of all patients with Duchenne muscular dystrophy, regardless of the genetic mutation responsible,” says Caroline Le Guiner, the main author of this study.
The Latest on: Duchenne muscular dystrophy
[google_news title=”” keyword=”Duchenne muscular dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- CureDuchenne Raises More Than $1.5 Million at Eighth Annual Napa in Newporton January 10, 2023 at 9:40 pm
Paula and Debra Miller received a phone call from their infant son’s doctor, telling them that their son, Hawken, was diagnosed with Duchenne Muscular Dystrophy, a devastating muscle disease that ...
- 1st certified Duchenne care center on Long Island opens at Stony Brook Children's Hospitalon January 10, 2023 at 5:50 pm
Duchenne muscular dystrophy, also known as DMD, is a genetic disorder that weakens skeletal and heart muscles causing cardiac and respiratory issues.
- FDA Sets Fall Date for Approval Decision on Vamorolone for DMDon January 10, 2023 at 9:26 am
The FDA is reviewing the corticosteroid vamorolone as a treatment for Duchenne muscular dystrophy and has set a decision date for October.
- Solid Biosciences Outlines Strategy For Leadership In Precision Genetic Medicines With Focus On Neuromuscular And Cardiac Diseaseson January 10, 2023 at 6:50 am
Investigational New Drug (IND) application for SGT-003, next-generation gene therapy for Duchenne muscular dystrophy utilizing novel capsid AAV ...
- Catalent made primary commercial manufacturing partner for Sarepta’s DMD gene therapy candidateon January 10, 2023 at 3:51 am
Catalent is to support the manufacture of Sarepta Therapeutics' gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).
- India on a mission to find ‘affordable’ cure for rare genetic disorder DMDon January 10, 2023 at 3:18 am
If Indian scientists are successful in their efforts, there could be finally an affordable treatment for Duchenne Muscular Dystrophy, a rare genetic disorder whose annual treatment cost in the country ...
- Warrnambool's Gillin Boys Foundation donates $50,000 to Duchenne Muscular Dystrophy researchon January 9, 2023 at 7:00 pm
A Warrnambool charity has made its second major contribution to muscular dystrophy research in a matter of months indicating the community's determination to find a cure for the condition.
- Duchenne Muscular Dystrophy Market Research Report 2023-2029on January 9, 2023 at 9:25 am
The "Duchenne Muscular Dystrophy Market" provides a value chain analysis of revenue for the anticipated period from 2023 ...
- Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophyon January 8, 2023 at 9:00 pm
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, January 9, 2023 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the U.S. Foo ...
- Indian researchers developing treatment for rare genetic disorder 'Duchenne Muscular Dystrophy'on January 8, 2023 at 5:58 am
The current therapeutic options available to treat DMD are minimal and highly expensive treatment with costs shooting up to Rs 2-3 crore per child a year and are mostly imported from abroad, ...
via Google News and Bing News